Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sacituzumab Govitecan in Recurrent or Persistent Cervical Cancer
NCT05838521Phase 2Recruiting
- Sponsor
- Yale University
- Start
- Jun 2023
- Primary completion
- Dec 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sacituzumab govitecan in Cervical Cancer (CC), sponsored by Yale University. Primary endpoint: Objective Response Rate at 4 years. Started Jun 2023; status: recruiting.
02
Drugs
sacituzumab govitecan
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT05838521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05838521.